Статья

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

Cristina MenniDepartment of Twin Research & Genetic Epidemiology, King's College London, London, UK. Electronic address: [email protected]Kerstin KläserSchool of Biomedical Engineering & Imaging Sciences, King's College London, London, UKAnna MayZOE Global, London, UKLorenzo PolidoriZOE Global, London, UKJoan Capdevila PujolZOE Global, London, UKPanayiotis LoucaDepartment of Twin Research & Genetic Epidemiology, King's College London, London, UKCarole H. SudreSchool of Biomedical Engineering & Imaging Sciences, King's College London, London, UK; Medical Research Council Unit for Lifelong Health and Ageing, Department of Population Science and Experimental Medicine, and Centre for Medical Image Computing, Department of Computer Science, University College London, London, UKLong H. NguyenClinical & Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USADavid A. DrewClinical & Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USAJordi MerinoDiabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USAChristina HuZOE Global, London, UKSomesh SelvachandranZOE Global, London, UKMichela AntonelliSchool of Biomedical Engineering & Imaging Sciences, King's College London, London, UKBenjamin MurraySchool of Biomedical Engineering & Imaging Sciences, King's College London, London, UKLiane S. CanasSchool of Biomedical Engineering & Imaging Sciences, King's College London, London, UKErika MolteniSchool of Biomedical Engineering & Imaging Sciences, King's College London, London, UKMark S. GrahamSchool of Biomedical Engineering & Imaging Sciences, King's College London, London, UKMarc ModatSchool of Biomedical Engineering & Imaging Sciences, King's College London, London, UKAmit D. JoshiClinical & Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USAMassimo ManginoDepartment of Twin Research & Genetic Epidemiology, King's College London, London, UK; National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' Foundation Trust, London, UKAlexander HammersSchool of Biomedical Engineering & Imaging Sciences, King's College London, London, UKAnna L. GoodmanDepartment of Infection, Guy's and St Thomas' Foundation Trust, St Thomas Hospital, London, UKAndrew T. ChanClinical & Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USAJonathan WolfZOE Global, London, UKClaire J. StevesDepartment of Twin Research & Genetic Epidemiology, King's College London, London, UKAna M. ValdesDepartment of Twin Research & Genetic Epidemiology, King's College London, London, UK; Nottingham NIHR Biomedical Research Centre at the School of Medicine, University of Nottingham, Nottingham City Hospital, Nottingham, UKSébastien OurselinSchool of Biomedical Engineering & Imaging Sciences, King's College London, London, UKTim D. SpectorDepartment of Twin Research & Genetic Epidemiology, King's College London, London, UK

2021en

ABI

Аннотация

BACKGROUND: The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase 3 trials. We aimed to investigate the safety and effectiveness of these vaccines in a UK community setting. METHODS: ), and comorbidities (binary variable, with or without comorbidities). FINDINGS: Between Dec 8, and March 10, 2021, 627 383 individuals reported being vaccinated with 655 590 doses: 282 103 received one dose of BNT162b2, of whom 28 207 received a second dose, and 345 280 received one dose of ChAdOx1 nCoV-19. Systemic side-effects were reported by 13·5% (38 155 of 282 103) of individuals after the first dose of BNT162b2, by 22·0% (6216 of 28 207) after the second dose of BNT162b2, and by 33·7% (116 473 of 345 280) after the first dose of ChAdOx1 nCoV-19. Local side-effects were reported by 71·9% (150 023 of 208 767) of individuals after the first dose of BNT162b2, by 68·5% (9025 of 13 179) after the second dose of BNT162b2, and by 58·7% (104 282 of 177 655) after the first dose of ChAdOx1 nCoV-19. Systemic side-effects were more common (1·6 times after the first dose of ChAdOx1 nCoV-19 and 2·9 times after the first dose of BNT162b2) among individuals with previous SARS-CoV-2 infection than among those without known past infection. Local effects were similarly higher in individuals previously infected than in those without known past infection (1·4 times after the first dose of ChAdOx1 nCoV-19 and 1·2 times after the first dose of BNT162b2). 3106 of 103 622 vaccinated individuals and 50 340 of 464 356 unvaccinated controls tested positive for SARS-CoV-2 infection. Significant reductions in infection risk were seen starting at 12 days after the first dose, reaching 60% (95% CI 49-68) for ChAdOx1 nCoV-19 and 69% (66-72) for BNT162b2 at 21-44 days and 72% (63-79) for BNT162b2 after 45-59 days. INTERPRETATION: Systemic and local side-effects after BNT162b2 and ChAdOx1 nCoV-19 vaccination occur at frequencies lower than reported in phase 3 trials. Both vaccines decrease the risk of SARS-CoV-2 infection after 12 days. FUNDING: ZOE Global, National Institute for Health Research, Chronic Disease Research Foundation, National Institutes of Health, UK Medical Research Council, Wellcome Trust, UK Research and Innovation, American Gastroenterological Association.

Перевод пока недоступен

Идентификаторы

DOI: 10.1016/s1473-3099(21)00224-3

Цитирования и источники

Цитирований: 3Использованных источников: 0

Показатели — AkademScholar